Business Wire

numares AG Achieves Key Milestone: Identifies Candidate Metabolomic Network for Bladder Cancer Diagnostics

13.7.2017 09:00 | Business Wire

Del

numares AG obtained promising results from a retrospective study that provides initial evidence that evaluation of metabolomic biomarker networks can be used as a non-invasive diagnostic for bladder cancer. Based on these results, the company enrolled patients in a prospective study to confirm and further refine the metabolomic network. The test is intended to be launched as a CE-marked in-vitro diagnostics (IVD) in Europe in the second half of 2018.

Bladder cancer can be challenging to diagnose. Available urine-based tests are often not reliable if there are traces of blood in the urine sample (called microhematuria), which is also associated with bladder cancer. However, even persistent microhematuria is a poor prognostic indicator, because only two to five percent of patients with microhematuria are diagnosed with bladder cancer. As a result, the majority of patients presenting with microhematuria undergo cystoscopy to rule out bladder cancer as a cause of the symptom. Cystoscopy is an invasive procedure that causes risks as well as pain for the patient. Thus, there is a significant need for a non-invasive bladder cancer screening test to reduce the number of cystoscopies.

To address this need, numares initiated a project to develop a non-invasive bladder cancer IVD test that would be run on AXINON ® , a fully-integrated laboratory system based on nuclear magnetic resonance (NMR) spectroscopy. The first step in the project was to evaluate approximately 300 urine samples from patients with and without bladder cancer with the objective of identifying metabolites that could be developed into a bladder cancer-specific metabolomic network.

“Based on this analysis, we have initiated and are currently finishing the recruitment phase of our prospective validation study, BLADE (Bladder Cancer Detection using Metabolomic Evaluation of Urine and Blood), to confirm our initial findings,” said Dr. Philipp Pagel, chief medical officer of numares. “We collected urine samples from patients with persistent microhematuria who are scheduled for cystoscopy. With this program, numares pursues the European Association of Urology’s (EAU) appeal to evaluate new biomarkers in urine for avoiding cystoscopies.”

“The positive results of our retrospective analysis were an important milestone for numares as the bladder cancer test has now advanced into the next phase,” said Volker Pfahlert, chairman of the executive board of numares. “When launched, the bladder cancer test will be our second metabolomic network-based diagnostic. The first, the recently-launched renalTX-SCORE®, uses a metabolomic biomarker network to diagnose kidney transplant rejection in urine samples. Along with renalTX-SCORE, the bladder cancer project further illustrates the power of the metabolomic biomarker network approach.”

About bladder cancer
Urinary bladder carcinoma is among the most common types of cancer with approximately 350,000 new cases per year. Men are significantly more often (3.8 times) affected than women. In Europe about 118,000 new cases were discovered in 2012. In the US there is an estimation of 80,000 new cases and 17,000 deaths by bladder cancer in 2017.

Bladder cancer is mostly associated with quite unspecific signs and symptoms, such as blood in the urine. If medical anamnesis and ultrasonic examination do not reveal the cause of the hematuria, as a next step a cystoscopy is recommended.

About biomarker networks
The innovative approach to use biomarker networks for diagnostic purposes becomes increasingly relevant for several further medical questions, which cannot be addressed by appropriate diagnostic solutions so far. It is numares’ mission to fulfill those unmet diagnostic needs by developing products for its NMR-based AXINON® IVD system. It is reflected by the company’s product pipeline. To achieve its mission, numares developed its proprietary Magnetic Group Signaling® (MGS®) technology as a prerequisite and employs machine learning techniques (also known as artificial intelligence) to process the large amount of data and to identify metabolomic biomarker networks.

About Magnetic Group Signaling ® (MGS ® )
Nuclear Magnetic Resonance (NMR) has long been used as a research tool, in particular for determining the structure of chemical compounds. In the past, this technology was too complex to be used in metabolomics-based medical research or diagnostics due to several technical limitations. numares developed its proprietary Magnetic Group Signaling® (MGS®) technology to enable NMR to answer demanding questions in metabolomics. With MGS®, important prerequisites like standardization and qualification can be fulfilled through technical processes and procedures. For the first time systematic processing and use of diagnostic information from the metabolism is possible. Thanks to MGS®, numares’ in vitro diagnostic system (IVD) AXINON® is able to generate reliable and reproducible data of highest quality – independent of the NMR device or the user. This enables fully automated analysis of patient samples without any human intervention.

About numares
numares AG is a fast-growing innovative diagnostics company that develops and markets software-based test systems for high-throughput use in clinical diagnostics and life science research. The AXINON® IVD system and its diagnostic tests employ nuclear magnetic resonance (NMR) spectroscopy creating a “numaric” spectrum with which to evaluate metabolomic networks. The output of these analyses provide physicians with valuable information on the disease status of patients. numares developed its proprietary Magnetic Group Signaling® (MGS®) technology to enable NMR for highly standardized and rapid throughput testing, making it a cost-efficient new solution for diagnostic purposes. The metabolomics tests address unmet medical needs in the indication fields of cardiovascular diseases, nephrology, oncology and neurology, shaping another important pillar in precision medicine. numares AG is headquartered in Regensburg, Germany, with offices in Boston and Singapore.

You will find more information at http://www.numares.com.

Contact information

numares AG
Dipl.-Biol. Christiane Proll, MBA
Tel.:
+49 941 2809 49-14
E-Mail: christiane.proll@numares.com
or
IRA WÜLFING KOMMUNIKATION GmbH
Dr. Reinhard Saller
Tel.: +49 89 2000 30-30
E-Mail: reinhard.saller@wuelfing-kommunikation.de
or
U.S.A.
The Ruth Group
Investors:
Robert Flamm, Ph.D.
Tel.: 1-646-536-7017
E-Mail: rflamm@theruthgroup.com
or
Media:
Kirsten Thomas/Cari Randall
Tel: 1-508-280-6592/1-646-536-7002
E-Mail: kthomas@theruthgroup.com /crandall@theruthgroup.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Natalia Vodianova Joins PicsArt as Head of Aspiration20.7.2017 13:00Pressemelding

PicsArt, the leading image editing app and creative social network, today announced the appointment of Natalia Vodianova, the supermodel and philanthropist, as Head of Aspiration. In this new role, Natalia will inspire and suggest opportunities to drive positive change through creativity. She has also joined the company’s advisory board. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720005372/en/ Natalia Vodianova, the supermodel and philanthropist, joins PicsArt as Head of Aspiration. (Photo: Business Wire) “We are thrilled to welcome a talent and role model like Natalia into our family,” said PicsArt CEO Hovhannes Avoyan. “Natalia has been deeply involved in bringing creative inspiration to the world through fashion and social commitment. She’ll help connect the fashion world and the

CloudHealth Technologies Expands Business in Europe20.7.2017 13:00Pressemelding

CloudHealth Technologies, the leader in cloud service management, today announced that it is expanding its customer base, partner list and business operations in the European region. Helping to fuel the expansion is $46 million in Series D funding, which the company secured in June. The funding round will help CloudHealth Technologies scale international operations and double the size of its global workforce. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720005189/en/ CloudHealth Technologies Expands Business in Europe (Photo: Business Wire) Cloud adoption in EMEA is growing steadily, with the market projected to reach €44.8 billion by the year 2020, according to Market Research & Statistics1. As enterprises turn to the cloud to build apps and manage operations, they improve

Pacific Drilling Announces Early Consent Deadline Results20.7.2017 13:00Pressemelding

Pacific Drilling V Limited (the “Issuer”), a wholly owned subsidiary of Pacific Drilling S.A. (NYSE: PACD) (together with its subsidiaries, the “Company”) announced today the results, as of 5:00 p.m. Eastern Daylight Time on July 19 (the “Early Consent Deadline”) of its previously announced private consent solicitation in respect of its 7.25% Senior Secured Notes due December 1, 2017 (the “Notes”) pursuant to which the Issuer is soliciting the consent of the holders of Notes to an extension of the maturity date of the Notes to June 1, 2018 in order to give the Company more time to negotiate a refinancing transaction or undertake a holistic restructuring with all of its creditors (the “Solicitation”). At the Early Consent Deadline, the Issuer has received consents of holders of the Notes comprising less than 66 2/3% of the aggregate principal amount of the Notes (disregarding Notes held by the

Watch BizWireTV: AR/VR Innovator Leap Motion Looks to Expand Globally and Stephen Curry, Serena Williams and Other Sports Stars Win Big at Nickelodeon’s Kids’ Choice Sports 201720.7.2017 12:08Pressemelding

On the latest BizWireTV, catch the latest Quick Biz Hits and who’s using some Star Power. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720005302/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Sponsored Headline The State of Channel Marketing: IDG Research study reveals crossroads, opportunity for channel marketers. Top of the Wire

21st Century Fox’s Response to Statement by the UK’s Secretary of State for Digital, Culture, Media and Sport20.7.2017 12:05Pressemelding

21st Century Fox (21CF) notes today’s statement by the Secretary of State for Digital, Culture, Media and Sport that she continues to consider the representations that have been made before she makes her decision on 21CF’s proposed acquisition of the remaining shares of Sky. We welcomed the recent statement by the Secretary of State that “Ofcom is unequivocal” regarding 21CF’s genuine commitment to broadcasting standards, following advice from the independent regulator which found “there are no broadcasting standards concerns which may justify a reference by the Secretary of State to the Competition and Markets Authority.” For over 25 years, 21CF and Sky have been proud broadcasters of good standing in the UK, a responsibility we take very seriously. We also welcomed Ofcom’s decision of 29th June that Sky would remain ‘fit and proper’ to hold a broadcasting licence after this proposed

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom